Figure 1



100
80
60
40
20
% Recovery by Poros A HPLC
i.v. bag 1
0 hours
i.v. bag 2
2 hour hold
i.v. bag 3
infusion
PVC (25 mL) i.v. bag
PVC (50 mL) i.v. bag
PO (25 mL) i.v. bag
PO (50 mL) i.v. bag
Sample and Timepoint

Figure 2



% Recovery by Poros A HPLC
100
90
80
70
60
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
Target concentration in bag, mg/mL
% recovery, 2 hour hold in i.v. bag
linear fit
% recovery, 2 hour infusion
exponential growth

Figure 3



MWM
RS
Met
Cys
Glut
MTG
EDTA
200 kDa
116.3 kDa
97.4 KDa
66.2 kDa
55.4 kDa
36.5 kDa
31 kDa
21.5 kDa
14.4 kDa

Figure 4



Formula Code | mAb mg/mL | PS80 % | Met mM | EDTA mM
C | 0.2 | 0.1 | 10 | 0.05
G | 0.2 | 0.1 | 0 | 0
H | 0.2 | 0 | 0 | 0
C_5°C
G_5°C
H_5°C
C_25°C
G_25°C
H_25°C
%oxidation at methionine residues 254
100
80
60
40
20
0
0
1
2
3
4
5
6
Time, months

Figure 5 depicts Otelixizumab Heavy Chain Amino Acid Sequence (SEQ ID NO: 1).

EVQLLESGGG LVQPGGSLRL SCAASGFTFS SFPMAWVRQA PGKGLEWVST
ISTSGGRTYY RDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFR
QYSGGFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYAS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK

Figure 6 depicts Otelixizumab Light Chain Amino Acid Sequence (SEQ ID NO: 2).

DIQLTQPNSV STSLGSTVKL SCTLSSGNIE NNYVHWYQLY EGRSPTTMIY
DDDKRPDGVP DRFSGSIDRS SNSAFLTIHN VAIEDEAIYF CHSYVSSFNV
FGGGTKLTVL RQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV
AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT
HEGSTVEKTV APTECS